Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 8/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | GNRHR | P30968 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5719008 | 0.96 | DPP4 (0.34) | DPP4ADORA2BKCNH2ADORA3TSHR | |
| SCHEMBL5719189 | 0.93 | DPP4 (0.37) | DPP4KCNH2TSHRSMN1; SMN2 | |
| SCHEMBL5719577 | 0.92 | DPP4 (0.35) | DPP4KCNH2HPGD | |
| SCHEMBL5719344 | 0.91 | DPP4 (0.33) | DPP4ADORA2BGNRHRTSHRSMN1; SMN2 | |
| SCHEMBL5718953 | 0.90 | DPP4 (0.35) | DPP4KCNH2SMN1; SMN2 | |
| SCHEMBL5719570 | 0.90 | KCNJ1 (0.36) | DPP4KCNH2 | |
| SCHEMBL5719273 | 0.90 | DPP4 (0.32) | DPP4KCNH2 | |
| SCHEMBL5719144 | 0.90 | DPP4 (0.43) | DPP4KCNH2 | |
| SCHEMBL5719298 | 0.89 | HTR2C (0.35) | DPP4ADORA2BKCNH2SMN1; SMN2 | |
| SCHEMBL5719084 | 0.89 | DPP4 (0.36) | DPP4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7074798-B2 | Xanthine derivative and DPPIV inhibitor | EISAI CO., LTD (JP) | 2006-07-11 | — | — | US | disclosed |
| EP-1338595-B1 | Xanthine derivatives as DPP-IV inhibitors | EISAI CO LTD (JP) | 2006-05-03 | — | — | EP | disclosed |
| US-20040082570-A1 | Xanthine derivative and DPPIV inhibitor | EISAI CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1338595-A2 | Xanthine derivatives as DPP-IV inhibitors | Eisai Co., Ltd. (JP) | 2003-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082570-A1 | Xanthine derivative and DPPIV inhibitor | DPP4, DPP9, DPP7 | DPP4 1/4885ADORA2B 269/4885KCNH2 1102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.